10-K: Stereotaxis Reports 2025 Revenue Growth Amid Losses

Stereotaxis, Inc. reported a 20% revenue increase in 2025, driven by system sales and disposable devices, alongside key regulatory approvals for new robotic navigation products, despite continued net losses.

Summary

• Total revenue increased 20% to $32.4 million in 2025 from $26.9 million in 2024.
• System sales revenue grew 18% to $10.2 million in 2025 from $8.6 million in 2024.
• Disposable interventional devices, service, and accessories revenue increased 21% to $22.2 million in 2025 from $18.3 million in 2024, partly due to the full-year contribution from the APT acquisition.
• Gross margin decreased slightly to 53% in 2025 from 54% in 2024, primarily due to changes in product mix.
• Operating loss improved to $(22.1) million in 2025 from $(24.7) million in 2024.
• Net loss was $(21.6) million in 2025, compared to $(24.0) million in 2024.
• System backlog as of December 31, 2025, was $9.1 million, down from $14.4 million at December 31, 2024; approximately 78% of the 2025 backlog is expected to be recognized as revenue in 2026.
• Cash and cash equivalents were $13.4 million at December 31, 2025, up from $12.2 million at December 31, 2024.
• Key regulatory approvals were achieved for GenesisX RMN System (FDA 510(k) in Q4 2025), Synchrony Solution (CE Mark in October 2025), MAGiC catheter (CE Mark in Q1 2025, FDA 510(k) in January 2026), and MAGiC Sweep catheter (FDA 510(k) in July 2025).
• The acquisition of Access Point Technologies EP, Inc. (APT) was completed on July 31, 2024, providing in-house catheter development and manufacturing expertise.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While revenue growth and new product approvals are positive, the continued significant net losses, increased cash burn from operations, and declining system backlog indicate ongoing financial challenges and a heavy reliance on capital raises.

Positives

• Total revenue increased by 20% year-over-year, driven by growth in both system sales (18%) and disposables, service, and accessories (21%).
• The acquisition of Access Point Technologies EP, Inc. (APT) in July 2024 contributed to the increase in disposable revenue and provides in-house catheter development and manufacturing expertise.
• Received FDA 510(k) regulatory clearance for the GenesisX RMN System in Q4 2025, designed to enhance accessibility by reducing installation time.
• Obtained CE Mark for the Synchrony Solution in October 2025, modernizing cath labs with 4K HD displays and cloud-based connectivity.
• The Stereotaxis MAGiC catheter received CE marking in Europe in Q1 2025 and FDA 510(k) clearance in January 2026, providing a proprietary robotically navigated ablation catheter.
• MAGiC Sweep, the first robotically navigated high-density EP mapping catheter, received FDA 510(k) clearance in July 2025.
• The Genesis RMN system received regulatory approval from China's NMPA in November 2024, expanding market access.
• Operating loss improved to $(22.1) million in 2025 from $(24.7) million in 2024.
• Cash and cash equivalents increased to $13.4 million at December 31, 2025, from $12.2 million at December 31, 2024.
• Successfully raised $8.5 million in gross proceeds from a registered direct offering in July 2025 and an additional $4.0 million in November 2025.
• Established an At-The-Market (ATM) Program for up to $50.0 million of common stock, with $3.1 million gross proceeds raised in 2025.
• Received approximately $0.5 million in an employee retention tax credit in Q2 2025.

Negatives

• The company incurred a net loss of $(21.6) million in 2025 and an accumulated deficit of $583.4 million as of December 31, 2025, and expects to continue incurring operating losses and negative cash flows.
• System backlog decreased to $9.1 million at December 31, 2025, from $14.4 million at December 31, 2024, indicating a reduction in future recognized revenue from existing orders.
• Gross margin slightly decreased to 53% in 2025 from 54% in 2024 due to product mix changes.
• The obligation of Johnson & Johnson (J&J) to supply co-developed catheters ended on December 31, 2025, and there are no guarantees of continued supply into 2026, which is of significant importance for many customers.
• Cash flow used in operating activities increased to $(13.7) million in 2025 from $(8.5) million in 2024, primarily due to changes in working capital.
• The company is highly dependent on the services of CEO David L. Fischel, and his compensation package, including the CEO Performance Award, may fail to retain him.
• The CEO Performance Award will incur significant additional stock-based compensation expense ($22.7 million remaining as of December 31, 2025) regardless of whether market capitalization milestones are achieved, increasing the difficulty of achieving profitability.
• The issuance of earnout consideration for the APT acquisition will result in dilution to stockholders, with an estimated 4,613,380 additional earnout common shares potentially issuable.
• The company's ability to utilize acquired net operating loss carryovers and tax credits from APT will be limited under IRC Section 382.

Risks

• May not generate cash from operations or be able to raise necessary capital to continue operations, potentially leading to curtailment or cessation of operations.
• Macroeconomic and geopolitical factors, including tariffs, supply chain challenges, inflationary pressures, elevated interest rates, and global conflicts, could adversely affect supply chain, hospital buying patterns, ability to raise capital, and disrupt business.
• Hospital decision-makers may not purchase robotic magnetic navigation systems or related products due to high cost or caution in adopting new technology.
• Inability to fulfill current purchase orders and commitments on a timely basis or at all may hinder future sales growth, as orders are subject to contingencies, revisions, modifications, or cancellations.
• Long and variable sales and installation cycles for robotic magnetic navigation systems can cause substantial fluctuations in quarterly results.
• Physicians may not use products if they do not believe they are safe, efficient, and effective, or due to perceived liability risks, potentially harming sales and profitability.
• Strategic collaborations with fluoroscopy system manufacturers and catheter/electrophysiology mapping system providers may fail, or new collaborations may not be established, disrupting commercialization efforts and revenue.
• The obligation of Johnson & Johnson to supply co-developed catheters ended on December 31, 2025, with no guarantee of continued supply into 2026, which is critical for many customers.
• Inability to effectively utilize or expand the sales force, accurately forecast sales, or manage unforeseen costs could impair revenue growth.
• Lack of physician willingness or time to commit to training for the sophisticated robotic magnetic navigation system could delay market acceptance.
• Intense competition from traditional interventional methods, new mapping/ablation systems, non-RF therapies, and other robotic technologies could render products obsolete or unmarketable.
• Magnetic fields generated by the system may be incompatible with or interfere with other interventional lab equipment, increasing installation costs or limiting adoption.
• Significant risks of product liability claims due to product use causing injury or death, potentially leading to expensive litigation, diversion of management attention, and reputational harm.
• Incurred substantial net losses since inception ($583.4 million accumulated deficit) and expects future losses, with uncertain timing of profitability.
• Dependence on contract manufacturers and single suppliers (e.g., magnets) for components poses risks of quality control issues, supply interruptions, increased costs, and inability to meet demand.
• Sourcing key components (magnets) from overseas (Japan, China) exposes the company to currency fluctuations, export restrictions, tariffs, trade regulations, political instability, and shipping delays.
• Problems at manufacturing facilities or subcontractors, or unexpected delays, could result in lost revenue.
• Substantial growth may strain resources, requiring improvements in information systems, procedures, controls, and workforce management.
• Inability to successfully integrate APT into the business, realize anticipated benefits, or effectively manage APT's catheter manufacturing business post-acquisition.
• Issuance of earnout consideration for the APT acquisition will result in dilution to stockholders and may adversely affect the market price of securities.
• May take actions to achieve APT earnout milestones that would not have been undertaken otherwise, potentially adversely affecting the historical business of Stereotaxis.
• Rate of product innovation might not keep pace with the market, or inability to ensure compatibility with other electrophysiology lab products.
• Security breaches and other disruptions to IT infrastructure could interfere with operations, compromise confidential information, and expose the company to liability.
• Inability to protect technology from third-party use, or third-party assertions of infringement, leading to expensive litigation or loss of rights.
• May not be able to maintain necessary licenses or rights from third parties for new and existing products.
• Limited resources may lead to failure in focusing on the most profitable medical applications for its technology.
• Subject to damages from claims of wrongful use or disclosure of former employers' trade secrets by employees.
• Discovery of software errors or other defects could damage business and reputation.
• Failure or delays in obtaining or maintaining necessary FDA clearances/approvals (U.S.) or regulatory approvals in other countries for medical devices.
• Failure to comply with ongoing FDA, EU, and other authorities' regulatory requirements (e.g., QSR, labeling, reporting) could lead to enforcement actions and penalties.
• Potential repeal or amendment of healthcare legislation (e.g., PPACA) could reduce reimbursement, change coverage policies, increase compliance costs, and delay hospital spending.
• State certificate of need regulations and customer compliance with licensing requirements could limit product sales.
• Hospitals/physicians may be unable to obtain reimbursement from third-party payors for procedures using products, or reimbursement may be insufficient.
• Significant number of warranty claims or other uninsured liabilities could substantially increase costs and harm reputation.
• Principal stockholders own a large percentage of voting stock, potentially influencing corporate actions and discouraging takeovers.
• Future issuances of securities (e.g., convertible preferred stock conversion, APT earnout shares, CEO Performance Award, shelf registration) could dilute current stockholders' ownership.
• Never paid dividends and does not anticipate paying cash dividends in the foreseeable future.
• Certificate of incorporation, bylaws, CEO Performance Share Unit Agreement, and Delaware law contain provisions that could discourage a takeover.
• Changing laws, regulations, and standards relating to corporate governance and public disclosure may result in additional expenses and uncertainty.
• Future operating results may fall below securities analysts' or investors' expectations, causing stock price decline.
• Common stock price could fluctuate substantially, possibly resulting in class action securities litigation.
• Failure to meet NYSE American Market requirements could lead to delisting, adversely affecting market liquidity and access to capital.
• Significant stock-based compensation expense for CEO Performance Award ($22.7 million remaining) regardless of milestone achievement, hindering profitability.
• Stockholders may experience substantial dilution (up to 13,000,000 shares for CEO) upon payout of shares under the CEO Performance Award.
• Provisions in the PSU Agreement may discourage a change in control.
• Highly dependent on the services of Mr. Fischel, and compensation package may fail to retain him.
• General economic conditions could materially adversely impact the company, causing customers to delay purchases or cancellations.
• Maintains cash balances exceeding federally insured limits, exposing the company to loss if banking institutions fail.
• May lose key personnel or fail to attract and retain replacement/additional personnel, harming business and ability to compete.
• Currency fluctuations, export restrictions, tariffs, political instability, war, and shipping delays associated with international operations.

Future Outlook

The company expects to continue incurring operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. Approximately 78% of the $9.1 million system backlog as of December 31, 2025, is anticipated to be recognized as revenue over 2026. The company plans to expand the clinical focus of its technology to additional endovascular indications, including coronary, neuro, and peripheral interventions, and is ramping up production of its proprietary MAGiC ablation catheter. Management believes current cash and cash equivalents will be sufficient to meet obligations for at least 12 months and beyond, with potential future financing through equity sales, non-core asset sales, strategic collaborations, or debt.

Management Comments

• "We have shared our aspirations and a product strategy to expand the clinical focus of our technology to several additional endovascular indications including coronary, neuro, and peripheral interventions."
• "The GenesisX RMN System, the latest generation of the Genesis RMN System, is designed to significantly enhance the accessibility of Robotic Magnetic Navigation by eliminating the lengthy construction cycle necessary to install prior generation RMN systems."
• "Synchrony digitizes and modernizes the interventional cath lab with a 4K high-definition display that consolidates the viewing and control of disparate systems in the lab, offering enhanced procedure experience with custom layouts, streamlined workflows, an intuitive user interface, and a decluttered environment."
• "The integration with APT provides in-house catheter development, manufacturing expertise and specialized knowledge that will further Stereotaxis innovation efforts in developing a broad family of interventional devices navigated by our robots within electrophysiology and across a range of endovascular procedures."
• "We continue to anticipate periodic disruptions to our manufacturing operations, supply chains, procedures volumes, service activities, and capital system orders and placements relating to new or ongoing periodic resurgences of pandemic-related issues, any of which could have a material adverse effect on our business, financial condition, results of operations, or cash flows."
• "We believe the cash, and cash equivalents on hand as of December 31, 2025, will be sufficient to meet its obligations as they become due in the ordinary course of business for at least 12 months following the date of the consolidated financial statements included in this Annual Report on Form 10-K, as well as for periods beyond that 12-month period."

Industry Context

StockSavvy.ai notes that the medical device market, particularly for cardiac ablation procedures, is a multi-billion-dollar industry with expectations for substantial long-term growth, driven by an aging population and increasing prevalence of arrhythmias. The company's focus on robotic magnetic navigation positions it within the growing trend of minimally invasive surgical techniques and automation in healthcare, aiming to address challenges in precision, safety, and efficiency that manual methods face. The expansion into coronary, neuro, and peripheral interventions aligns with broader industry efforts to apply robotic assistance across a wider range of complex endovascular procedures.

Comparison to Industry Standards

• The company states it is the only company that has commercialized remote, digital, and direct control of the working tip of catheters for use in RF ablation procedures.
• It acknowledges competition from traditional catheter-based electrophysiology ablation approaches (RF and non-RF therapies), next-generation mapping systems, and non-RF ablation devices (e.g., single-shot cryoablation, pulse field ablation) from established players like Biosense Webster (Johnson & Johnson).
• Mentions awareness of four companies that commercialized endovascular catheter navigation systems cleared by FDA for electrophysiology, and two with electromagnetic catheter navigation systems with CE Mark, but notes none seem active in catheter robotics with current commercial activities.
• Identifies at least two companies with commercialized robotic systems for guidewire manipulation as potential competitors in non-electrophysiology interventional procedures.
• Notes two other companies that produce and sell magnetically enabled catheters, directly competing with its own MAGiC line.
• Faces direct competition in its Odyssey/Synchrony Solution from established imaging companies and dedicated solution providers.

Corporate Governance

Legal Proceedings

• The company is involved from time to time in various lawsuits and claims arising in the normal course of business.
• As of December 31, 2025, the company had $4.3 million of insurance receivables and $4.3 million of legal contingencies recorded related to ongoing litigation.
• The company believes it has substantial defenses to these claims and does not believe any are presently likely to have a material adverse effect on business, financial condition, or results of operations.
• In February 2024, a vendor filed financing statements under the Uniform Commercial Code (UCC) on underlying inventory for approximately $0.6 million, which the company is contesting.

Stakeholder Impact

• Shareholders face potential for significant dilution from future equity issuances (Series A Convertible Preferred Stock conversion, APT earnout shares, CEO Performance Award, ATM program).
• Continued net losses and negative cash flow could negatively impact the stock price for shareholders.
• Principal stockholders have substantial influence over corporate actions.
• Employees benefit from new product approvals and the company's commitment to attracting, developing, and retaining talent, including competitive compensation, benefits, and training.
• Customers (hospitals/physicians) benefit from new product approvals (GenesisX RMN, Synchrony, MAGiC, MAGiC Sweep) offering improved precision, safety, efficiency, and reduced x-ray exposure.
• Customers face risks including potential delays in system installation, supply chain disruptions affecting catheter availability (e.g., J&J catheters), and challenges in obtaining reimbursement.
• Suppliers and vendors face risks related to the company's reliance on contract manufacturers and single-sourced suppliers, which could lead to supply chain disruptions and increased costs.
• Creditors are currently not significantly impacted as the company reported no debt as of December 31, 2025, and liquidity is supported by cash and equity raises.

Next Steps

• Ramp up production of the proprietary MAGiC ablation catheter to replace J&J catheters.
• Obtain necessary regulatory approvals for MAGiC Sweep and EMAGIN 5F catheter guide in other geographies.
• Continue efforts to ensure the availability of compatible systems and devices and/or equivalent alternatives from strategic relationships.
• Continue to evaluate the macroeconomic business environment and take action to increase inventory levels and engage with vendors on contractual obligations.
• Design and implement strategic initiatives to effectively manage APT's catheter manufacturing business and integrate it into the combined business.
• Continue to pursue sales under the ATM Program and potentially other equity or debt financings to fund operations.
• Continue to invest in research and development to expand clinical focus to coronary, neuro, and peripheral interventions.

Key Dates

Recommendation

The company shows promising product innovation and revenue growth, particularly in disposables, driven by recent acquisitions and regulatory approvals. However, persistent operating losses, negative cash flow from operations, and a declining system backlog indicate that the company is still in a high-growth, high-investment phase with uncertain profitability. The reliance on capital raises and the significant dilution potential from the CEO Performance Award and APT earnouts warrant caution. Investors should hold, monitoring the successful commercialization of new products, the resolution of supply chain dependencies, and progress towards sustainable profitability.

Keywords

Robotic Magnetic Navigation, Electrophysiology, Cardiac Ablation, Medical Devices, GenesisX RMN System, Synchrony Solution, MAGiC Catheter, Map-iT Catheters, FDA Clearance, CE Mark, Interventional Cardiology, Arrhythmias, Healthcare Technology, SEC Filing, 10-K, STXS